A Double-blind, Placebo-Controlled, Randomized, 4-Week, Multiple-Dose, Proof-of-Mechanism Study in Subjects With Prodromal Alzheimer's Disease Investigating the Effects of JNJ-54861911 on Abeta Processing in CSF and Plasma

Trial Profile

A Double-blind, Placebo-Controlled, Randomized, 4-Week, Multiple-Dose, Proof-of-Mechanism Study in Subjects With Prodromal Alzheimer's Disease Investigating the Effects of JNJ-54861911 on Abeta Processing in CSF and Plasma

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Jun 2015

At a glance

  • Drugs JNJ 54861911 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 24 Jun 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 29 Jan 2015 Planned primary completion date changed from 1 Dec 2014 to 1 Apr 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top